Company intelligence / Profile preview

Betaliq, Inc.

Tampa, Florida, United States

Ownership: Private
Development stage: Phase 2

Overview

Betaliq has completed Phase 2a trials for BTQ1902 (timolol suspension) with positive results and is advancing toward Phase 3 clinical trials. The company has also initiated enrollment for Phase 2 clinical trials investigating BTQ-1901-A, BTQ-1901-B, and BTQ-1902 for the treatment of glaucoma or ocular hypertension[4][6].

Therapeutic areas: Ophthalmology
Modalities: Small molecules (beta blockers)
Industry: Biotech

Drug pipeline

3 assets

BTQ2302

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Novaliq GmbHBLP Management Group, LLC

Beyond the preview

Go deeper on Betaliq, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Betaliq, Inc..

Explore the full profile